Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
| 19.6 | |
| 19.6 | |
| - | |
| 19.6 | |
| 19.6 | |
| 14.75-19.6 | |
| 12 266 M | |
| 33.7931 | |
| 624 M | |
| 478 105 M | |
| 0.1135 | |
| 0.0098 | |
| 0.655 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Global strategic alliance to leverage Sysmex’s Plasma-Safe-SeqS technology QIAGEN will use ultra-sensitive liquid biopsy applications in oncology Alliance boosts QIAGEN’s co-development of compa...
Global strategic alliance to leverage Sysmex’s Plasma-Safe-SeqS technology QIAGEN will use ultra-sensitive liquid biopsy applications in oncology Alliance boosts QIAGEN’s co-development of compa...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
